key: cord-0873097-jsxbaww0
authors: Arora, Prerna; Kempf, Amy; Nehlmeier, Inga; Graichen, Luise; Winkler, Martin S.; Lier, Martin; Schulz, Sebastian; Jäck, Hans-Martin; Cossmann, Anne; Stankov, Metodi V.; Behrens, Georg M.N.; Pöhlmann, Stefan; Hoffmann, Markus
title: SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
date: 2022-04-15
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110754
sha: 31eee9581b7c520283a70586e8ee5a538f52a20d
doc_id: 873097
cord_uid: jsxbaww0

Rapid spread of SARS-CoV-2 variants C.1.2 and B.1.621 (Mu variant) in Africa and the Americas, respectively, as well as a high number of mutations in the viral spike proteins raised concerns that these variants might pose an elevated threat to human health. Here, we show that C.1.2 and B.1.621 spike proteins mediate increased entry into certain cell lines but do not exhibit increased ACE2 binding. Further, we demonstrate that C.1.2 and B.1.621 are resistant to neutralization by Bamlanivimab but remain sensitive to inhibition by antibody cocktails used for COVID-19 therapy. Finally, we show that C.1.2 and B.1.621 partially escape neutralization by antibodies induced upon infection and vaccination, with escape of vaccine-induced antibodies being as potent as that measured for B.1.351 (Beta variant), which is known to be highly neutralization resistant. Collectively, C.1.2 and B.1.621 partially evade control by vaccine induced antibodies, suggesting that close monitoring of these variants is warranted.

The repeated emergence of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) 32 variants with increased transmissibility and/or reduced neutralization sensitivity threatens our efforts to 33 combat the COVID-19 (coronavirus disease 2019) pandemic though vaccination. To date, five SARS-34

CoV-2 variants are classified as variants of concern (VOCs) -Alpha (B.1.1.7 and sublineages), Beta 35 respectively, both C.1.2 S proteins were more efficient in mediating entry into Vero (~2.5x/~2.0x C.1.2 118 "early"/C.1.2 "late") and 293T (~3.0x/~3.1x C.1.2 "early"/C.1.2 "late") cells ( Figure 1E and 119

Supplementary Figure 1A) . For the remaining two cell lines (Huh-7 and H1299), C.1.2 and B.1.621 S 120 proteins displayed ~1.5x (Huh-7) and ~4.0x (H1299) higher entry efficiency compared to B.1 S ( Figure  121 1E and Supplementary Figure 1A) . 122

Since C.1.2 "early", C.1.2 "late" and B.1.621 harbor several mutations at RBD residues that directly 123 interact with ACE2 ( Figure 2A and B), we further investigated whether augmented cell entry stems from 124 increased S protein binding to ACE2. For this, we employed a flow cytometric assay and a Cell-based 125 ACE2 Binding Assay (CABA) with soluble ACE2 and S proteins transiently expressed in 293T-cells. 126

Using these techniques, we did not observe significant differences in ACE2 binding between the S 127 proteins studied ( Figure 2C and Supplementary Figure 1B for COVID-19 treatment. In order to assess whether C.1.2 "early", C. to which the mAbs bind to are known, mapping the mutated amino acid residues of C.1.2 "early", C.1.2 141 "late" and B.1.621 suggested that neutralization by Casirivimab, Bamlanivimab and Etesevimab might 142 be compromised ( Figure 2D ). 143 J o u r n a l P r e -p r o o f 8 Consistent with the findings from the in silico-analysis, we observed partial loss of neutralization by 144 Casirivimab (~3.0x-7.4x increase in IC50, likely due to mutation E484K) and Etesevimab (~3.2x-11.4x 145 increase in IC50, likely due to mutations Y449H [only C.1.2 S proteins] and N501Y), and complete 146 resistance against Bamlanivimab (likely due to mutation E484K). In contrast, neutralization by 147 Imdevimab was unaffected ( Figure 2D and E, Supplementary Figure 1D ). However, although individual 148 mAbs (partially) lost their neutralizing potential, mAb cocktails remained highly potent ( Figure 2E , 149

Supplementary Figure 1D ). In keeping with published data, particles bearing B.1.351 S were completely We neither observed significant differences in cell entry between the two C.1.2 S proteins nor major 210 changes in neutralization sensitivity. Therefore, it remains speculative whether the additional mutations 211 found in C.1.2 "late" may endow the virus with an advantage that could not be identified in this study, 212 potentially usage of additional attachment-promoting factors not expressed in the tested cell lines. 213

Alternatively, C.1.2 "Late" may have spread as the result of a founder effect, e.g. because C.1.2 "Late" 214 may have been introduced into regions that are more populated or populations with more social contacts. 215

In sum, this study provides evidence for increased host cell entry, resistance to therapeutic options 216 (full/partial resistance against therapeutic antibodies) and partial evasion of preexisting immunity 217 (antibodies elicited upon infection or vaccination) by SARS-CoV-2 variants C.1.2 and B.1.621. 218

However, while a less robust preexisting immunity may still protect against infection and/or developing 219 severe disease upon infection with C.1.2 and B.1.621 the chance of becoming infected with these 220 variants is higher as compared to variants that cannot escape antibody neutralization with high potency. 221

As a consequence, efforts to contain the spread of these variants are warranted and surveillance programs 222 should screen for both variants in order to detect small C.1.2-and B.1.621-related infection clusters 223 before they grow too big to be contained. 224

Our study has the following limitations: we employed VSV pseudotyped with SARS-CoV-2 S proteins 227 to study cell entry and its neutralization by antibodies. Although these vectors faithfully recapitulate 228 SARS-CoV-2 cell entry and thus represent a widely accepted surrogate model, our results await formal 229 confirmation with authentic virus. Furthermore, host cell entry was studied using immortalized cell lines, 230 and these analyses should be extended to primary cell cultures and in vivo models. 

-All data reported in this paper will be shared by the lead contact upon request.

-This paper does not report original code.

-Any additional information required to reanalyze the data reported in this paper is 320 available from the lead contact upon request. The production of soluble ACE2 has been described elsewhere in detail (Hoffmann et al., 2021c) . 415

Briefly, 293T cells were seeded and transfected with expression plasmid for soluble ACE2. After 416 overnight incubation, the medium was replaced and the cells further incubated for 38 h before the 417 supernatant was collected and centrifuged to remove any cell debris. Further, the culture supernatant 418 was concentrated using a Vivaspin protein concentrator column (molecular weight 30 kDa; Sartorius). 419

The concentrated soluble ACE2 was aliquoted and stored at -80 °C for further use. 420

In order to test ACE2 binding of soluble ACE2 to S protein, 293T cells were seeded in 6-well plates and quadruplicates. For data normalization, the plasma/serum dilution factor that leads to 50% reduction in 495 S protein-driven cell entry (neutralizing titer 50, NT50) was calculated. In addition, for each 496 plasma/serum the fold change in NT50 between SARS-CoV 2 B.1 (set as 1) and the indicated variants 497 was calculated. Table S1 : COVID-19 patient data (Related to Figure 2) . 509 510 Table S2 : Vaccinated patient data (Related to Figure 2) . 511 512 

The neutralizing antibody, LY-CoV555, 569 protects against SARS-CoV-2 infection in nonhuman primates

Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus 572 Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization

Tracking Changes in SARS-CoV-2 Spike: Evidence that 575 D614G Increases Infectivity of the COVID-19 Virus

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-578 induced immunity

N-terminal domain antigenic mapping reveals a site of vulnerability 581 for SARS-CoV-2

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. The New England 589 journal of medicine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 592 against Covid-19

CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

BNT162b2 and ChAdOx1 nCoV-19 Vaccine 597 Effectiveness against Death from the Delta Variant

A 599 human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Complete map of SARS-CoV-2 RBD 601 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited 605 antibodies of previously infected individuals

N501Y mutation 607 of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2

Neutralization of the SARS-CoV-2 Mu Variant by 610 Convalescent and Vaccine Serum

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 613 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South 614 Africa, and the UK

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. The 617

Structural and Functional Analysis of the D614G SARS

The authors thank Roberto Cattaneo, Georg Herrler, Stephan Ludwig, Andrea Maisner, Thomas

 1 and 2) :(A) Pseudotype entry data presented in Figure 1E normalized against the assay background. The experiment was performed as described in the legend of Figure 1E with the difference that pseudotype entry was normalized against signals obtained from cells inoculated with particles bearing no viral glycoprotein (background, set as 1). Further, entry of particles bearing VSV-G is shown. Error bars indicate the standard error of the mean (SEM).(B) Unprocessed data on ACE2 binding analyzed by flow cytometry (related to Figure 2C ). 293T expressing the indicated S proteins following transfection were incubated with soluble ACE2 (ACE2 ectodomain fused to an Fc-tag derived from human IgG) and AlexaFluor-488-conjugated anti-human antibody and analyzed flow cytometry. The Presented are the individual neutralization results for the data presented in Figure 2F